BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 20491646)

  • 1. Positron Emission Tomography and Computer Tomography (PET/CT) in Prostate, Bladder, and Testicular Cancers.
    Zouhair A; Ozsahin M; Schaffer M; Albrecht S; Camus F; Jichlinski P; Mirimanoff RO; Bischof Delaloye A; Meuwly JY; Prior JO
    Curr Med Chem; 2010; 17(23):2492-502. PubMed ID: 20491646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Value of positron emission tomography and computer tomography (PET/CT) for urologic malignancies].
    Boujelbene N; Prior JO; Boubaker A; Azria D; Schaffer M; Gez E; Jichlinski P; Meuwly JY; Mirimanoff RO; Ozsahin M; Zouhair A
    Cancer Radiother; 2011 Jul; 15(4):307-15. PubMed ID: 21507695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET/Computed Tomography in Renal, Bladder, and Testicular Cancer.
    Bouchelouche K; Choyke PL
    PET Clin; 2015 Jul; 10(3):361-74. PubMed ID: 26099672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recommendation for clinical practice: use of PET-FDG in cancer of the kidney, prostate, testicles, and the urinary bladder].
    Bourguet P; Planchamp F; Montravers F; Vincendeau S; Courbon F; Edeline V; Helal BO; Rossi D; Villers A; ; ; ; ; ; ; ;
    Bull Cancer; 2006 Dec; 93(12):1228-32. PubMed ID: 17191352
    [No Abstract]   [Full Text] [Related]  

  • 5. Recent developments in urologic oncology: positron emission tomography molecular imaging.
    Bouchelouche K; Oehr P
    Curr Opin Oncol; 2008 May; 20(3):321-6. PubMed ID: 18391633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [2006 technology monitoring report: clinical practice guideline: use of FDG-PET in kidney, prostate, testis and bladder cancers].
    Bourguet P; Planchamp F; Montravers F; Vincendeau S; ;
    Prog Urol; 2007 Apr; 17(2):172-5. PubMed ID: 17489312
    [No Abstract]   [Full Text] [Related]  

  • 7. Positron-emission tomography imaging in urological oncology: Current aspects and developments.
    Rauscher I; Eiber M; Weber WA; Gschwend JE; Horn T; Maurer T
    Int J Urol; 2018 Nov; 25(11):912-921. PubMed ID: 30103285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoplasms of the bladder, prostate, and testis.
    Heiken JP; Forman HP; Brown JJ
    Radiol Clin North Am; 1994 Jan; 32(1):81-98. PubMed ID: 8284363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG in Urologic Malignancies.
    Høilund-Carlsen PF; Poulsen MH; Petersen H; Hess S; Lund L
    PET Clin; 2014 Oct; 9(4):457-68, vi. PubMed ID: 26050947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET in prostate and bladder tumors.
    Lee ST; Lawrentschuk N; Scott AM
    Semin Nucl Med; 2012 Jul; 42(4):231-46. PubMed ID: 22681672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission tomography in urologic oncology.
    Shvarts O; Han KR; Seltzer M; Pantuck AJ; Belldegrun AS
    Cancer Control; 2002; 9(4):335-42. PubMed ID: 12228759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asymptomatic Solitary Metastasis to the Testis From Prostate Carcinoma Detected by FDG PET/CT.
    Hsieh TC; Lin CC; Kao CH; Wu YC; Sun SS
    Clin Nucl Med; 2016 Jan; 41(1):86-7. PubMed ID: 26402135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible role of FDG-PET in the evaluation of urologic malignancies.
    Bender H; Schomburg A; Albers P; Ruhlmann J; Biersack HJ
    Anticancer Res; 1997; 17(3B):1655-60. PubMed ID: 9179213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in Imaging in Prostate and Bladder Cancer.
    Srivastava A; Douglass LM; Chernyak V; Watts KL
    Curr Urol Rep; 2017 Sep; 18(9):69. PubMed ID: 28718164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positron emission tomography (PET) in the urooncological evaluation of the small pelvis.
    Machtens S; Serth J; Meyer A; Kleinhorst C; Ommer KJ; Herbst U; Kieruij M; Boerner AR
    World J Urol; 2007 Aug; 25(4):341-9. PubMed ID: 17624533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
    Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
    Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomography in uro-oncology.
    Hain SF
    Cancer Imaging; 2005 Jan; 5(1):1-7. PubMed ID: 16154810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour functional imaging by PET.
    Abrantes AM; Pires AS; Monteiro L; Teixo R; Neves AR; Tavares NT; Marques IA; Botelho MF
    Biochim Biophys Acta Mol Basis Dis; 2020 Jun; 1866(6):165717. PubMed ID: 32035103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in urological cancers].
    Bourguet P;
    Bull Cancer; 2003 Feb; 90 Spec No():S80-7. PubMed ID: 12739339
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.